(Press-News.org) WASHINGTON, DC — A preclinical study led by researchers at Children's National Medical Center has found that a new oral drug shows early promise for the treatment of Duchenne muscular dystrophy (DMD). The results, published in EMBO Molecular Medicine, show that the drug, VBP15, decreases inflammation and protects and strengthens muscle without the harsh side effects linked to current treatments with glucocorticoids such as prednisone.
Duchenne muscular dystrophy results in severe muscle degeneration and affects approximately 180,000 patients worldwide, mostly children. The current standard treatment uses glucocorticoids, but is limited due to serious side effects leading to fragile bones and suppression of both the immune system and growth.
"These findings, while preliminary, are very promising for advancing the treatment of this disease, which causes disability in so many children worldwide," said Eric P. Hoffman, PhD, director of the Center for Genetic Medicine Research at Children's National. "The study also suggests the potential for new strategies in very early treatment, which could further benefit patients."
The Children's National research team also observed that VBP15 inhibits the transcription factor NF-κB, a key cell-signaling molecule found in most cell types that plays a role in inflammation and tissue damage. The team previously found that NF-κB is active in dystrophin-deficient muscle years before the onset of symptoms, suggesting that very early treatment of Duchenne muscular dystrophy patients with VBP15 may prevent or delay the onset of some clinical symptoms.
"VBP15 has an additional property of addressing membrane defects in dystrophic muscle cells," remarked Kanneboyina Nagaraju, DVM, PhD, the lead author of the study, and principal investigator in the Center for Genetic Medicine at Children's National. "It is becoming increasingly clear that membrane integrity and repair are crucial factors not only in muscle, but also in cardiovascular, neurodegenerative, and airway disorders. In-creasing pre-clinical data suggest that VBP15 may show efficacy in these other disorders and in many other indications where steroids are used." Dr. Nagaraju noted.
Initial clinical trials of VBP15 are planned, pending Food and Drug Administration (FDA) review and approval, anticipated in 2014. ReveraGen Biopharma, Inc., the first Children's National private spin-off company, is working closely with Children's National investigators to translate the pre-clinical findings to DMD patients. ReveraGen Biopharma collaborated with NIH/TRND on VBP15, which was selected through a national com-petitive process, one of the few inaugural compounds selected through this novel pro-gram.
"The partnership with NIH and support from many others is illustrative of the importance of private-public partnerships that are essential in expediting the development of orphan disease therapeutics," remarked Edward Connor, MD, CEO, and CMO of ReveraGen Biopharma and Director of Innovation Development at Children's National. "We are optimistic that the new drug will translate well to patients, and are moving this forward as quickly as possible, while assuring safety."
###
In addition to the support from the National Institutes of Health, the VBP15 study was also funded through the U.S. Department of Defense, Muscular Dystrophy Association, Foundation to Eradicate Duchenne, and CureDuchenne Foundation.
Contact: Emily Hartman or Paula Darte, Children's National Medical Center, 202-476-4500
About EMBO
EMBO is an organization of more than 1500 leading researchers that promotes excellence in the life sciences. The major goals of the organization are to support talented researchers at all stages of their careers, stimulate the exchange of scientific information, and help build a European re-search environment where scientists can achieve their best work.
EMBO helps young scientists to advance their research, promote their international reputations and ensure their mobility. Courses, workshops, conferences and scientific journals disseminate the latest research and offer training in techniques to maintain high standards of excellence in research practice. EMBO helps to shape science and research policy by seeking input and feedback from our community and by following closely the trends in science in Europe. For more information: http://www.embo.org
About Children's National Medical Center
Children's National Medical Center in Washington, DC, has been serving the nation's children since 1870. Home to Children's Research Institute and the Sheikh Zayed Institute for Pediatric Surgical Innovation, Children's National is consistently ranked among the top pediatric hospitals by U.S.News & World Report and the Leapfrog Group. Children's National is a Magnet® designated hospital. With 303 beds and eight regional outpatient centers, Children's National is the premier provider of pediatric medical services in the Washington metropolitan area. For more information, visit ChildrensNational.org, or follow us on Facebook and Twitter.
About ReveraGen Biopharma
Reveragen Biopharma is a privately held drug development company focused on development of anti-inflammatory and personalized medicine products, with an emphasis on neuromuscular dis-ease. Reveragen's lead compound, VBP15, shows efficacy in animal models of chronic inflam-mation, including Duchenne muscular dystrophy, inflammatory bowel disease, cystic fibrosis, sickle cell anemia, and asthma. The key advance of VBP15 is the separation and optimization of the different sub-activities of frequently prescribed steroid drugs – transrepression, transactivation, and physicochemical membrane properties. This has enabled the selection of a candidate drug that retains or improves efficacy, but minimizes side effect profiles in pre-clinical models. Reveragen began through technology transfer from Children's National Medical Center and receives development support from NIH TRND, MDA VP, US Department of Defense CDRMP, Foundation to Eradicate Duchenne, and CureDuchenne.
END
WASHINGTON, Sept. 17, 2013—Scientists seeking new ways to fight cancer often try to understand the subtle, often invisible, changes to DNA, proteins, cells, and tissue that alter the body's normal biology and cause disease. Now, to aid in that fight, a team of researchers has developed a sophisticated new optical imaging tool that enables scientists to look deep within tumors and uncover their inner workings. In experiments that will be described at Frontiers in Optics (FiO), The Optical Society's (OSA) Annual Meeting, Dai Fukumura and his colleagues will present new optical ...
Production scale, not lower labor costs, drives China's current advantage in manufacturing photovoltaic (PV) solar energy systems, according to a new report released today by the Energy Department's National Renewable Energy Laboratory (NREL) and the Massachusetts Institute of Technology (MIT). Although the prevailing belief is that low labor costs and direct government subsidies for PV manufacturing in China account for that country's dominance in PV manufacturing, the NREL/MIT study shows that a majority of the region's current competitive advantage comes from production ...
It can take up to two and a half turns to steer a modern vehicle. While turning, the driver must release the wheel in the necessary hand-over-hand movement, which is unsafe. In his upcoming HFES 2013 Annual Meeting paper, Rene Guerster, who has been concerned with steering improvement since he was a child, proposes an alternative steering device that could help to prevent hazards such as rear-end collisions and rollovers caused by panic oversteering. He will present his work on October 4 at the Hilton San Diego Bayfront Hotel.
Severe sudden turns are extremely difficult ...
Putnam Valley, NY. (Sept. 17, 2013) –A research team in Spain has developed high-yield preparations of viable hepatocytes (liver cells) isolated for transplantation from cryopreserved (frozen), banked neonatal livers that ranged in age from one day to 23 days. The researchers also assessed cell quality and function and found that neonatal hepatocytes show better thawing recovery than hepatocytes isolated from adult livers.
The study appears as an early e-publication for the journal Cell Transplantation, and is now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/pre-prints/content-cog_09636897_ct1036tolosa
"There ...
Traditional peer review is not enough to ensure data quality amid the recent boom in scientific research findings, according to results of a 10-year collaboration between the National Institute of Standards and Technology (NIST) and five technical journals.
While production of research data is growing about 7 percent annually, about one-third of papers submitted to participating journals contained erroneous or incomplete chemical property data, according to a report by 32 authors from NIST and the collaborating journals.* Poor data can lead to mistakes in equipment selection, ...
The proclivity of Spaniards to bask in regions like the Costa del Sol while their northern European counterparts must stay under cover to protect their paler skin or risk skin cancer is due in large part to the pigment producing qualities of the MC1R gene locus. The MC1R gene, expressed in skin and hair follicle cells, is more diverse in Eurasian populations compared to African populations.
Now, a team of researchers led by Santos Alonso, et. al., have examined the evolutionary selective pressure for MC1R among a large population of Spaniards in comparison to their Northern ...
Diversity of microbial growth strategies in a limited nutrient world
The budding yeast, Saccharomyces cerevisiae, is a prime organism for studying fundamental cellular processes, with the functions of many proteins important in the cell cycle and signaling networks found in human biology having first been discovered in yeast.
Now, scientists from New York University have now developed a sophisticated assay to track cell growth at very low nutrient concentrations. The assay uses time-lapse microscopy to monitor individual yeast cells undergoing a small number of divisions ...
(SACRAMENTO, Calif.) — Children with a genetic disorder called 22q11.2 deletion syndrome, who frequently are believed to also have autism, often may be misidentified because the social impairments associated with their developmental delay may mimic the features of autism, a study by researchers with the UC Davis MIND Institute suggests.
The study is the first to examine autism in children with chromosome 22q11.2 deletion syndrome, in whom the prevalence of autism has been reported at between 20 and 50 percent, using rigorous gold-standard diagnostic criteria. The research ...
Pregnant women with a body mass index (BMI) that is too high or too low are more likely to have maternal complications, require additional hospital care and incur higher medical costs, according to a new study published today (18 September) in BJOG: An International Journal of Obstetrics and Gynaecology.
The study was carried out in collaboration between researchers at the Universities of Edinburgh and Aberdeen, and the Information Services Division of NHS Scotland. It used routine obstetric records in Scotland, between 2003-2010, to investigate the impact of pregnant ...
DURHAM, N.C. -- Explorers need good maps, which they often end up drawing themselves.
Pursuing their interests in using the brains of birds as a model for the human brain, an international team of researchers led by Duke neuroscientist Erich Jarvis and his collaborators Chun-Chun Chen and Kazuhiro Wada have just completed a mapping of the bird brain based on a 10-year exploration of the tiny cerebrums of eight species of birds.
In a special issue appearing online in the Journal of Comparative Neurology, two papers from the Jarvis group propose a dramatic redrawing ...
